Results 201 to 210 of about 663,024 (297)

Neonatal seizures: Advances in diagnosis and management

open access: yesEpilepsia Open, EarlyView.
Abstract The International League Against Epilepsy (ILAE) created the ILAE Neonatal Task Force that classified neonatal seizures, defined neonatal epilepsy syndromes, and specified treatment guidelines. These frameworks, in addition to improved access to genetic testing and other recent advances, have revolutionized the diagnosis and management of ...
Elissa G. Yozawitz   +2 more
wiley   +1 more source

The multiple hit model of infantile and epileptic spasms: The 2025 update

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou   +6 more
wiley   +1 more source

Self‐completed patient‐reported outcome measures in adults with epilepsy: A review

open access: yesEpilepsia Open, EarlyView.
Abstract Epilepsy affects 65 million people worldwide, and is a World Health Organization priority disease as highlighted in their 2022–2031 Intersectoral Global Action Plan (IGAP) on Epilepsy and other Neurological Disorders. IGAP's objectives include improving epilepsy treatment and care.
Alison L. Conquest   +5 more
wiley   +1 more source

Late‐onset unexplained epilepsy as a risk factor for cognitive impairment and dementia: Protocol for a multi‐center prospective longitudinal observational study (ELUCID)

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Late‐onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10%–25% of individuals with LoUE develop dementia within 3–4 years following their first seizure.
Alice D. Lam   +13 more
wiley   +1 more source

Stiripentol use in Dravet syndrome patients in the USA: Results of a real‐world study

open access: yesEpilepsia Open, EarlyView.
Abstract Objective Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with a high seizure burden and mortality risk. Stiripentol, one of the first DS‐specific therapies, received FDA approval in 2018 but its real‐world use and impact post‐approval in the USA remain insufficiently characterized.
Elaine Wirrell   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy